{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"For acute myeloid leukemia (AML): Revised Recommendations of the International Working Group (IWG) Response Criteria for AML: CR: Free of leukemia-related symptoms, absolute neutrophil count (ANC) \\> 1.0 x 10\\^9/L, platelet count ≥ 100 x 10\\^9/L, normal bone marrow with \\< 5% blasts and no Auer rods. CRi: As per CR but w/ residual thrombocytopenia (platelet count \\<100 x 10\\^9/L) or residual neutropenia (ANC \\<1.0 x 10\\^9/L). PR: ≥50% decrease bone marrow blasts to 5 - 25% abnormal cells, or CR w/ ≤ 5% blasts if Auer rods present.\n\nFor myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML): Modified IWG Response Criteria for MDS: CR: Free of leukemia-related symptoms, ANC ≥1.0 x 10\\^9/L, platelet count ≥100 x 10\\^9/L, bone marrow ≤5% myeloblasts, normal maturation of all cell lines, hemoglobin ≥ 11g/dL, no blasts in the peripheral blood. PR: All CR criteria w/ ≥50% decrease in bone marrow blasts over pre-treatment, but still \\> 5%.","groups":[{"description":"E6201 240 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG000","title":"E6201 240 mg/m^2 Weekly"},{"description":"E6201 320 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG001","title":"E6201 320 mg/m^2 Weekly"},{"description":"E6201 160 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG002","title":"E6201 160 mg/m^2 Twice Weekly"},{"description":"E6201 240 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG003","title":"E6201 240 mg/m^2 Twice Weekly"},{"description":"E6201 320 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG004","title":"E6201 320 mg/m^2 Twice Weekly"}],"paramType":"NUMBER","populationDescription":"The analysis population was the per-protocol set (PPS). The PPS included all subjects in the FAS who had a valid baseline and one or more post-treatment assessments for a specified measure.","reportingStatus":"POSTED","timeFrame":"At the end of C1 and every 2 cycles thereafter through 6 months following last dose of study drug","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Objective Responses"}